This chapter reviews the potential of a treatment approach that uses psilocybin, a novel psychoactive drug, to ameliorate the psychospiritual distress and demoralization that often accompany a life-threatening cancer diagnosis. The focus of cutting-edge research beginning in the 1950s, the investigation of classic hallucinogens had a major impact on the evolving field of psychiatry, contributing to early discoveries of basic neurotransmitter systems and to significant developments in clinical psychopharmacology. While published reports of therapeutic breakthroughs with difficult-to-treat and refractory patient populations were initially met with mainstream professional enthusiasm, by the late 1960s and early 1970s the growing association of hallucinogens with widespread indiscriminate use led to the temporary abandonment of this promising psychiatric treatment model. After a hiatus lasting several decades, however, regulatory and scientific support has grown for the resumption of clinical research investigations exploring the safety and efficacy of a treatment model utilizing the classic hallucinogen, psilocybin, in a subject population that had previously demonstrated positive therapeutic response, patients with existential anxiety due to a life-threatening cancer diagnosis.
- Palliative Care
- Advanced Cancer Patient
- Mystical Experience
- Terminal Cancer Patient
- Existential Anxiety
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, access via your institution.
Berringer K. Der mescalinrausch. Berlin: Springer; 1927.
Bleuler M. Comparison of drug-induced and endogenous psychoses in man. In: Breatly PB, Deniker R, Raduco-Thomas D, editors. Proceedings of the first international congress of neuropsychopharmacology. Amsterdam: Elsevier; 1958.
Brady MJ, Peterman AH, Fitchett G, Mo M, Cella D. A case for including spirituality in quality of life measurement in oncology. Psychooncology. 1999;8:417–28.
Breitbart W, Gibson C, Chochinov HM. Palliative care. In: Levenson JL, editor. The American psychiatric publishing textbook of psychosomatic medicine. Washington, DC: American Psychiatric Publisher; 2005.
Breitbart W, Rosenfeld B, Pessin H, Kaim M, Funesti-Esch J, Galietta M, Nelson CJ, Brescia R. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. J Am Med Assoc. 2000;284:2907–11.
Breitbart W, Rosenfeld B, Gibson C, Pessin H, Poppito S, Nelson C, Tomarken A, Kosinski A, Berg A, Jacobson C, Sorger B, Abbey J, Olden M. Meaning-centered group psychotherapy for patients with advanced cancer: a pilot randomized controlled trial. Psychooncology. 2010;19:21–8.
Blinderman C, Cherny N. Existential issues do not necessarily result in existential suffering: lessons from cancer patients in Israel. Palliat Med. 2005;19:371–80.
Bucke RM. Cosmic consciousness. Philadelphia, PA: Innes & Sons; 1901.
Cassel EJ. The nature of suffering and the goals of medicine. N Engl J Med. 1982;306:639–45.
Chandler AL, Hartman MA. Lysergic acid diethylamide (LSD-25) as a facilitating agent in psychotherapy. Arch Gen Psychiatry. 1960;2:286–9.
Chochinov HM, Wilson KG, Lander S. Depression, hopelessness, and suicidal ideation in the terminally ill. Psychosomatics. 1998;39:336–70.
Chochinov HM, Hack T, Hassard T, Krisjanson L, McClemont S, Harlos M. Understanding the will to live in patients nearing death. Psychosomatics. 2005;46:7–10.
Chochinov HM, Cann BJ. Interventions to enhance the spiritual aspects of dying. J Palliat Med. 2005;8(Supplement 1):S103–15.
Chochinov HM, Hack T, Hassard T, Kristjanson LJ, McClemont S, Harlos M. Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life. J Clin Oncol. 2005;23:5520–5.
Cohen S. LSD and the anguish of dying. Harper’s. 1965 Sept: 69–78
Cohen SR, Mount BM, Tomas JN, Mount LF. Existential well-being is an important determinant of quality of life. Cancer. 1996;77:576–86.
Derogatis LR, Morrow GR, Fetting J, Penman D, Piasetsky C, Schmale AM, Henrichs M, Carnicke CL. J Am Med Assoc. 1983;249:751–7.
Doblin R. Pahnke’s Good Friday experiment: a long-term follow-up and methodological critique. J Transpersonal Psychol. 1991;23:1–28.
Durkin I, Kearney M, O’Siorain L. Psychiatric disorder in a palliative care unit. Palliat Med. 2003;17: 212–8.
Edwards A, Pang N, Shiu V, Chan C. The understanding of spirituality and the potential role of spiritual care in end-of-life and palliative care: a meta-study of qualitative research. Palliat Med. 2010;24(8):753–70.
Fernsler J, Klemm P, Miller M. Spiritual well-being and demands of illness in people with colorectal cancer. Cancer Nurs. 1999;22:134–40.
Field M, Cassel C, editors. Approaching death: improving care at the end-of-life. Washington, DC: National Academy Press; 1997.
Fisher G. Psychotherapy for the dying: principles and illustrative cases with special reference to the use of LSD. Omega. 1970;1:3–15.
Frankl VE. Man’s search for meaning. Boston, MA: Beacon; 1984.
Frankl VF. The will to meaning: foundations and applications of logotherapy. New York: Penguin; 1988.
Galfin JM, Walkins ER, Harlow T. Psychological distress and rumination in palliative care patients and their caregivers. J Palliat Med. 2010;13: 1345–8.
Greenberg L, Lantz MS, Likourezos A, Burack OR, Chichin E, Carter J. Screening for depression in nursing home palliative care patients. J Geriatr Psychiatry Neurol. 2004;17:212–8.
Griffiths RR, Grob CS. Hallucinogens as medicine. Sci Am. 2010;303(December):77–9.
Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011;218:649–65.
Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006;187:268–83.
Griffiths RR, Richards WA, Johnson MW, McCann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008;22(6):621–32.
Grinspoon L, Bakalar JB. Psychedelic drugs reconsidered. New York: Basic Books; 1979.
Grinspoon L, Bakalar JB. Can drugs be used to enhance the psychotherapeutic process? Am J Psychother. 1986;40:393–404.
Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer G. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68:71–8.
Grof S, Goodman LE, Richards WA, Kurland AA. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry. 1973;8:129–44.
Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose effects study. Psychopharmacology (Berl). 2004;172:145–56.
Henoch I, Danielson E. Existential concerns among patients with cancer and interventions to meet them: an integrative literature review. Psychooncology. 2009;18:225–36.
Henry M, Cohen R, Lee V, Sauthier P, Provencher D, Drouin P, Gauthier P, Gotlieb W, Lau S, Drummond N, Gilbert L, Stanimir G, Sturgeon J, Chasen M, Mitchell J, Nixon Huang L, Ferland M, Mayo N. The meaning making intervention (MMi) appears to increase meaning in life in advanced ovarian cancer: a randomized controlled pilot study. Psychooncology. 2010;19:1340–7.
Hills J, Paice JA, Cameron JR, Shott S. Spirituality and distress in palliative care consultation. J Palliat Med. 2005;8:782–8.
Hofmann A. LSD—my problem child: reflections on sacred drugs, mysticism and science. Los Angeles, CA: J.P. Tarcher; 1985.
Hotoph M, Chidgey J, Addington-Hall J, Ly KL. Depression in advanced disease: a systematic review. Part 1. Prevalence and case finding. Palliat Med. 2002;16:81–97.
Hotopf M, Price A. Palliative care psychiatry. Psychiatry. 2009;8:212–5.
Huxley A. The perennial philosophy. New York: Harper & Brothers; 1945.
Isbell H. Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia. 1959;1:29–38.
Jacob P, Shulgin AT. Structure-activity relationships of the classic hallucinogens and their analogs. NIDA Res Monogr. 1994;146:74–91.
James W. The varieties of religious experience. New York: Longman’s Green, and Co.; 1919.
Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22:603–20.
Jones JM, Huggins MA, Rydall AC, Rodin GM. Symptomatic distress, hopelessness, and the desire for hastened death in hospitalized cancer patients. J Psychosom Res. 2003;55:411–8.
Jung C. Psychology and religion. New Heaven, CT: Yale University Press; 1938.
Kandasamy A, Chaturvedi S, Desai G. Spirituality, distress, depression, anxiety, and quality of life in patients with advanced cancer. Indian J Cancer. 2011;48:55–8.
Kast EC. The measurement of pain, a new approach to an old problem. J New Drugs. 1962;2:344–51.
Kast EC, Collins VJ. Lysergic acid diethylamide as an analgesic agent. Anesth Analg. 1964;43:285–91.
Kelly B, Burnett P, Pelusi D, Badger S, Varghese F, Robertson M. Terminally ill cancer patients’ wish to hasten death. Palliat Med. 2002;16:339–45.
Kissane D, Clarke DM, Street AF. Demoralization syndrome-A relevant psychiatric diagnosis for palliative care. J Palliat Care. 2001;17:12–21.
Kluver H. Mescal: the ‘Divine’ plant and its psychological effects. London: Keegan Paul; 1928.
Lajoie DH, Shapiro SI. Definitions of transpersonal psychology: the first twenty-three years. J Transpersonal Psychol. 1992;24:79–98.
Lee V. The existential plight of cancer: meaning making as a concrete approach to the intangible search for meaning. Support Care Cancer. 2008;16:779–85.
LeMay K, Wilson KG. Treatment of existential distress in life threatening illness: a review of manualized interventions. Clin Psychol Rev. 2008;28: 472–93.
Lethborg C, Aranda S, Cox S, Kissane D. To what extent does meaning mediate adaptation to cancer? The relationship between physical suffering, meaning in life, and connection to others in adjustment to cancer. Palliat Support Care. 2007;5:377–88.
Lin HR, Bauer-Wu SM. Psycho-spiritual well-being in patients with advanced cancer: an integrative review of the literature. J Adv Nurs. 2003;44:69–80.
Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004;32:57–71.
Maslow AH. Religions, values, and peak experience. Columbus, OH: Ohio State University Press; 1964.
McClain CS, Rosenfeld B, Breitbart W. Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients. Lancet. 2003;361:1603–7.
McMillan SC, Weitzner M. How problematic are various aspects of quality of life in patients with cancer at the end of life? Oncol Nurs Forum. 2000;27:817–23.
Metzner R. Teonanacatl: sacred mushroom of visions. Verona, CA: Four Trees Press; 2004.
Moadel A, Morgan C, Fatone A, Grennan J, Carter J, Laruffa G, Skummy A, Dutcher J. Seeking meaning and hope: self-reported spiritual and existential needs among an ethnically-diverse cancer population. Psychooncology. 1999;8:378–85.
Moreno FA, Wiegand CB, Taitano K, Delgado PL. Safety, tolerability and efficacy of psilocybin in patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67:1735–40.
Morita T, Tsunoda J, Inoue S, Chihara S. An exploratory factor analysis of existential suffering in Japanese terminally ill cancer patients. Psychooncology. 2000;9:164–8.
Murata H. Spiritual pain and its care in patients with terminal cancer: construction of a conceptual framework by philosophical approach. Palliat Support Care. 2003;1:15–21.
National Institute for Clinical Excellence. Improving supportive and palliative care for adults with cancer. London: National Institute for Clinical Excellence; 2004.
The National Comprehensive Cancer Network: Distress Management Clinical Practice Guidelines in Oncology. www.NCCN.org(2009; 2010)
Nelson CJ, Rosenfeld B, Breitbart W, Galietta M. Spirituality, religion, and depression in the terminally ill. Psychosomatics. 2002;43:213–20.
Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101:131–81.
Osmond H. A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci. 1957;66:418–34.
Otto R. The idea of the holy. London: Oxford University Press; 1923.
Pahnke W. Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. Thesis presented to the President and Fellows of Harvard University for the Ph.D. in Religion and Society; 1963
Pahnke WN. The psychedelic mystical experience in the human encounter with death. Harvard Theol Rev. 1969;62:1–21.
Passie T. A history of the use of psilocybin in psychotherapy. In: Metzner R, editor. Teonanacatl: sacred mushroom of vision. El Verano, CA: Four Trees Press; 2004.
Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. 2002;7:357–64.
Presti DE, Nichols DE. Biochemistry and neuropharmacology of psilocybin mushrooms. In: Metzner R, editor. Teonanacatl: sacred mushroom of vision. El Verano, CA: Four Trees Press; 2004.
Puchalski C, Ferrell B, Virani R, Otis-Green S, Baird P, Bull J, Chochinov M, Handzo G, Nelson-Becker H, Prince-Paul M, Pugliese K, Sulmasy D. Improving the quality of spiritual care as a dimension of palliative care: the report of the consensus conference. J Palliat Med. 2009;12:885–904.
Puchalski CM, Romer AL. Taking a spiritual history allows clinicians to understand patients more fully. J Palliat Med. 2000;3:129–37.
Puchalski CM, Kilpatrick SD, McCullough ME, Larson DB. A systematic review of spiritual and religious variables in Palliative Medicine, American Journal of Hospice and Palliative Care, Hospice Journal, Journal of Palliative Care, and Journal of Pain and Symptom Management. Palliat Support Care. 2003;1:7–13.
Richards WA, Rhead JC, DiLeo FB, Yensen R, Kurland AA. The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychedelic Drugs. 1977;9:1–10.
Riedlinger TJ. The sacred mushroom seeker: essays for R. Gordon Wasson. Portland, OR: Dioscorides Press; 1990.
Rodin G, Lo C, Mikulincer M, Donner A, Gagliese L, Zimmermann C. Pathways to distress: the multiple determinants of depression, hopelessness, and the desire for hastened death in metastatic cancer patients. Soc Sci Med. 2009;68:562–9.
Rodin G, Zimmermann C, Rydall A, Jones J, Shepherd FA, Moore M, Fruh M, Donner A, Gagliese L. The desire for hastened death in patients with metastatic cancer. J Pain Symptom Manage. 2007;6: 661–75.
Rousseau P. Spirituality and the dying patient. J Clin Oncol. 2000;18:2000–2.
Saunders CM. The management of terminal malignant disease. London: Edward Arnold; 1978.
Saunders C. Spiritual pain. J Palliat Care. 1988;4: 29–32.
Schultes RE, Hofmann A. Plants of the gods: their sacred, healing and hallucinogenic powers. Rochester, VT: Healing Arts Press; 1992.
Sinclair S, Pereira J, Raffin S. A thematic review of the spirituality literature within palliative care. J Palliat Med. 2006;9:464–79.
Storey P, Knight CF. UNIPAC Two: alleviating psychological and spiritual pain in the terminally ill. Gainesville, FL: American Academy of Hospice and Palliative Medicine; 1997.
Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One. 2010;5: 1–19.
Tanyi RA. Towards clarification of the meaning of spirituality. J Adv Nurs. 2002;39:500–9.
Vachon M, Fillion L, Achille M. A conceptual analysis of spirituality at the end of life. J Palliat Med. 2009;12:53–7.
Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 1997;16:357–72.
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9:3897–902.
Weisman AD. Early diagnosis of vulnerability in cancer patients. Am J Med Sci. 1976;271:187–96.
Weisman AD, Worden JW. The existential plight in cancer: significance of the first 100 days. Int J Psychiatry Med. 1976;7:1–15.
Wilson KG, Chochinov HM, de Faye BJ, Breitbart W. Diagnosis and management of depression in palliative care. In: Chochinov HM, Breitbart W, editors. Handbook of psychiatry in palliative medicine. New York: Oxford University Press; 2000. p. 25–49.
Wilson KG, Chochinov HM, Skirko MG, Allard P, Chary S, Gagnon PR, Macmillan K, De Luca M, O’Shea F, Kuhl D, Fainsinger RL, Clinch JJ. Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manage. 2007;33:118–29.
World Health Organization: WHO definition of palliative care. www.who.int/cancer/palliative/definition.en/(2011). Accessed Feb 2011
Editors and Affiliations
Rights and permissions
© 2013 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Grob, C.S., Bossis, A.P., Griffiths, R.R. (2013). Use of the Classic Hallucinogen Psilocybin for Treatment of Existential Distress Associated with Cancer. In: Carr, B., STEEL, J. (eds) Psychological Aspects of Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-4866-2_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-4865-5
Online ISBN: 978-1-4614-4866-2
eBook Packages: MedicineMedicine (R0)